Date / Time
The goal of this activity is to improve the knowledge and competence of learners in integrating emerging antibody–drug conjugate therapies into lung cancer treatment paradigms.
This program is intended for global medical oncologists and other healthcare providers who care for patients with lung cancer.
Upon completion of this activity, participants should be able to:
- Identify features that affect the efficacy and toxicity of antibody–drug conjugates
- Assess clinical data for antibody drug conjugates being studied in advanced NSCLC
- Explain rationale and assessments of HER2 and other antibody drug conjugate targets in NSCLC
- Evaluate emerging strategies for using antibody drug conjugates to overcome EGFR-TKI resistance
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.